High-throughput screening for internalizing antibodies by homogeneous fluorescence imaging of a pH-activated probe

Journal of Biomolecular Screening

Volumn 21, Issue 1, 2016, Pages 12-23

  Riedl, Thilo ^a   Van Boxtel, Egon ^a   Bosch, Martijn ^a   Parren, Paul W H I ^a,b   Gerritsen, Arnout F ^a  

^a GENMAB   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody internalization; Antibody drug conjugates; High throughput screening; Homogenous assay; pH dependent dye

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; CETUXIMAB; CYTOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT DYE;

ANTIBODY LIBRARY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL ORGANELLE; CONTROLLED STUDY; ENDOSOME; FLUORESCENCE IMAGING; HIGH THROUGHPUT SCREENING; HUMAN; INTERNALIZATION; PH; PRIORITY JOURNAL; TRANSIENT EXPRESSION; BIOASSAY; DIAGNOSTIC IMAGING; FLUORESCENCE; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANTIBODIES; BIOLOGICAL ASSAY; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FLUORESCENCE; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYDROGEN-ION CONCENTRATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, CYTOKINE;

EID: 84951048516     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115613270     Document Type: Article

References (29)

1. Reichert J., Marketed Therapeutic Antibodies Compendium. mAbs 2012, 4, 413-415.
2. Campoli M., Ferris R., Ferrone S., et al. Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies. Clin. Cancer Res. 2010, 6, 11-20.
3. Sievers E. L., Senter P. D., Antibody-Drug Conjugates in Cancer Therapy. Annu Rev. Med. 2013, 64, 15-29.
4. Rudnick S. I., Lou J., Shaller C. C., et al. Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors. Cancer Res. 2011, 71, 2250-2259.
5. Chaparro-Riggers J., Liang H., DeVay R. M., et al. Increasing Serum Half-Life and Extending Cholesterol Lowering In Vivo by Engineering Antibody with pH-Sensitive Binding to PCSK9. J. Biol. Chem. 2012, 287, 11090-11097.
6. Lammerts van Bueren J. J., Bleeker W. K., Bogh H. O., et al. Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action. Cancer Res. 2006, 66, 7630-7638.
7. Schmidt M. M., Thurber G. M., Wittrup K. D., Kinetics of Anti-Carcinoembryonic Antigen Antibody Internalization: Effects of Affinity, Bivalency and Stability. Cancer Immunol. Immunother. 2008, 57, 1879-1890.
8. Boyer C. M., Pusztai L., Wiener J. R., et al. Relative Cytotoxic Activity of Immunotoxins Reactive with Different Epitopes on the Extracellular Domain of the c-erbB-2(HER/2neu) Gene Product 185. Int. J. Cancer 1999, 82, 525-531.
9. Nordberg E., Friedman M., Gostring L., et al. Cellular Studies of Binding Internalization and Retention of a Radiolabeled EGFR-Binding Affibody Molecule. Nucl. Med. Biol. 2007, 34, 609-618.
10. Michel R. B., Mattes M. J., Intracellular Accumulation of the Anti-CD20 Antibody 1F5 in B-Lymphoma Cells. Clin. Cancer Res. 2002, 8, 2701-2713.
11. Perera R. M., Zoncu R., Johns T. G., et al. Internalization, Intracellular Trafficking, and Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody. Neoplasia 2007, 9, 1099-1110.
12. Adie E. J., Francis M. J., Davies J., et al. CypHer 5: A Generic Approach for Measuring Activation and Trafficking of G Protein-Coupled Receptors in Live Cells. Assay Drug Dev. Technol. 2003, 1, 251-259.
13. Danielczyk A., Stahn R., Faulstich D., et al. PankoMab: A Potent New Generation Anti-Tumour MUC1 Antibody. Cancer Immunol. Immunother. 2006, 55, 1337-1347.
14. Klussman K., Mixan B. J., Cerveny C. G., et al. Secondary mAb-vcMMAE Conjugates Are Highly Sensitive Reporters of Antibody Internalization via the Lysosome Pathway. Bioconjug. Chem. 2004, 15, 765-773.
15. Briggs M. S., Burns D. D., Cooper M. E., et al. A pH-Sensitive Fluorescent Cyanine Dye for Biological Applications. J. Chem. Soc. Chem. Commun. 2000, 23, 2323-2324.
16. Beletskii A., Cooper M., Sriraman P., et al. High-Throughput Phagocytosis Assay Utilizing a pH-Sensitive Fluorescent Dye. Biotechniques 2005, 39, 894-897.
17. Rust S., Guillard S., Sachsenmeier K., et al. Combining Phenotypic and Proteomic Approaches to Identify Membrane Targets in a 'Triple Negative' Breast Cancer Cell Type. Mol. Cancer 2013, 12, 11.
18. Fishwild D. M., O'Donnell S. L., Bengoechea T., et al. High-Avidity Human IgG Kappa Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice. Nat. Biotechnol. 1996, 14, 845-851.
19. Bleeker W. K., Lammerts van Bueren J. J., van Ojik H. H., et al. Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy. J. Immunol. 2004, 173, 4699-4707.
20. de Goeij B. E., Peipp M., de Haij S., et al. HER2 Monoclonal Antibodies That Do Not Interfere with Receptor Heterodimerization-Mediated Signaling Induce Effective Internalization and Represent Valuable Components for Rational Antibody-Drug Conjugate Design. mAbs 2014, 6, 392-402.
21. Breij E. C., de Goeij B. E., Verploegen S., et al. An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors. Cancer Res. 2014, 74, 1214-1226.
22. Miraglia S., Swartzman E. E., Mellentin-Michelotti J., et al. Homogeneous Cell- and Bead-Based Assays for High Throughput Screening Using Fluorometric Microvolume Assay Technology. J. Biomol. Screen 1999, 4, 193-204.
23. Zhang J. H., Chung T. D. Y., Oldenburg K. R., A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67-73.
24. Carpenter G., Cohen S., 125I-Labeled Human Epidermal Growth Factor: Binding, Internalization, and Degradation in Human Fibroblasts. J. Cell Biol. 1976, 71, 159-171.
25. Lammerts van Bueren J. J., Bleeker W. K., Brännström A., et al. The Antibody Zalutumumab Inhibits Epidermal Growth Factor Receptor Signaling by Limiting Intra- and Intermolecular Flexibility. Proc. Natl. Acad. Sci. USA 2008, 105, 6109-6114.
26. Koefoed K., Steinaa L., Nielsen Søderberg J., et al. Rational Identification of an Optimal Antibody Mixture for Targeting the Epidermal Growth Factor Receptor. mAbs 2011, 3, 584-595.
27. Sittampalam G. S., Gal-Edd N., Arkin M., et al., eds. Assay Guidance Manual; Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda, MD, 2004. http://www.ncbi.nlm.nih.gov/books/NBK53196/
28. Mathejczyk J. E., Pauli J., Dullin C., High-Sensitivity Detection of Breast Tumors In Vivo by Use of a pH-Sensitive Near-Infrared Fluorescence Probe. J. Biomed. Opt. 2012, 17, 076028-1-076028-9.
29. de Goeij B. E., Satijn D., Freitag C., et al. High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates. Mol. Cancer Ther. 2015, 14, 1130-1140.